OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/01/2026
Back to search
Official data from USPTO
ANZUPGO (DELGOCITINIB)
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/03/2026
Trademark type
Combined
Nice classes
5, 38, 42, 44
Filing date
10/09/2023
Registration date
02/18/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/18/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
84
Owner location
DK
Examiner
MANCA, ALBERTO I
Law office
L80
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the black stylized wording "ANZUPGO" placed above the black stylized wording "(DELGOCITINIB)". To the left of this wording is placed a design of a green curved band.
Holders and representatives
Holders
LEO Pharma A/S
Representatives
B. Brett Heavner Finnegan, Henderson, Farabow, Garrett &
Technical classification
Nice Classes
Class 5Class 38Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of skin diseasesincluding hand eczema and chronic hand eczema; the foregoing containing delgocitinib as the primary ingredient
Class 38
Providing online forums for information and communication about skin diseasesincluding hand eczema and chronic hand eczema
Class 42
Scientific and medical research in the field of skin diseases; pharmaceutical research and development in the field of skin diseases; scientific research for medical purposes in the field of skin diseases; medical and pharmaceutical tests of pharmaceutical preparations being testing of pharmaceuticals in the field of skin diseases; providing information and consulting services in the field of medical and scientific research and pharmaceutical products development related to skin diseases and treatment of the skin; providing scientific information and scientific consulting services in the field of science related to skin diseases and treatment of the skin
Class 44
Medical services in the field of skin diseases; medicalhealth and pharmaceutical consultation in the field of skin diseases
Publications
History of USPTO decisions and trademark events.
29 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/17/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/17/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/19/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/01/2025
FIMP
FINAL DISPOSITION PROCESSED
09/01/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/18/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/31/2024
PUBO
PUBLISHED FOR OPPOSITION
12/31/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/25/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/26/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/26/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/26/2024
ATRV
ATTORNEY REVIEW COMPLETED
11/05/2024
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
10/28/2024
RFNT
REFUSAL PROCESSED BY IB
07/20/2024
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
07/20/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/25/2024
RFRR
REFUSAL PROCESSED BY MPU
06/25/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/14/2024
CNRT
NON-FINAL ACTION WRITTEN
05/29/2024
DOCK
ASSIGNED TO EXAMINER
05/28/2024
MAFR
APPLICATION FILING RECEIPT MAILED
01/02/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/29/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/28/2023
Continuous trademark protection
Get notified about every new filing that threatens ANZUPGO (DELGOCITINIB) or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.